What is Leerink Partnrs’ Estimate for AXSM FY2028 Earnings?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities researchers at Leerink Partnrs decreased their FY2028 EPS estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Friday, February 21st. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of $9.30 per share for the year, down from their previous estimate of $9.70. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.74) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ FY2029 earnings at $16.05 EPS.

Several other research analysts have also commented on AXSM. Royal Bank of Canada boosted their price objective on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 19th. Leerink Partners boosted their price objective on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday, February 10th. Cantor Fitzgerald reiterated an “overweight” rating and set a $153.00 price objective on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. Truist Financial boosted their price objective on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Finally, Wells Fargo & Company boosted their price objective on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, Axsome Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $158.79.

Axsome Therapeutics Trading Up 6.7 %

NASDAQ:AXSM opened at $137.75 on Monday. Axsome Therapeutics has a one year low of $64.11 and a one year high of $139.13. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.37 and a current ratio of 2.11. The firm has a market cap of $6.72 billion, a P/E ratio of -23.00 and a beta of 1.05. The firm has a 50-day simple moving average of $101.29 and a 200-day simple moving average of $94.99.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The business had revenue of $118.77 million during the quarter, compared to analyst estimates of $117.83 million.

Institutional Trading of Axsome Therapeutics

Several institutional investors have recently modified their holdings of the stock. TFG Asset Management GP Ltd purchased a new stake in Axsome Therapeutics in the 4th quarter valued at $3,490,000. GF Fund Management CO. LTD. purchased a new stake in Axsome Therapeutics in the 4th quarter valued at $86,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new stake in Axsome Therapeutics in the 4th quarter valued at $2,853,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Axsome Therapeutics by 20.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,642 shares of the company’s stock valued at $4,877,000 after purchasing an additional 9,928 shares during the last quarter. Finally, Woodline Partners LP raised its position in Axsome Therapeutics by 36.8% in the 4th quarter. Woodline Partners LP now owns 408,441 shares of the company’s stock valued at $34,558,000 after purchasing an additional 109,872 shares during the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Insider Activity at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now owns 42,187 shares of the company’s stock, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 22.40% of the stock is owned by corporate insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.